 |
> 2003 Publications
1.
Surrogate end point for prostate cancer-specific mortality
after radical prostatectomy or radiation therapy.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen M:
JNCI, 95:1376-83, 2003. 
Abstract
| 
PDF |
2.
Diagnostic Potential Of Serum Proteomic Patterns In
Prostate Cancer.
Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam B-L,
McLeod DG, Moul JW and Srivastava S:
J. Urol., 170:442-6, 2003.
Abstract
|
PDF |
3.
Factors associated with blood loss during radical prostatectomy
for localized prostate cancer in the prostate-specific antigen
(PSA)-era: an overview of the Department of Defense (DOD) Center
for Prostate Disease Research (CPDR) national database.
Moul JW, Sun L, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton
W, Kusuda L, Chung A, Soderdahl D, Donahue T.
Urol Oncol. 21:447-55,2003.
Abstract
|
PDF |
4. PMEPA1, an androgen-regulated NEDD4-binding protein,
exhibits cell growth inhibitory function and decreased expression
during prostate cancer progression.
Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, Sesterhenn
IA, McLeod DG, Sun L, Moul JW, Srivastava S.
Cancer Res. 63: 4299-304, 2003.
Abstract
|
PDF |
5. Using the percentage of biopsy cores positive for cancer,
pre-treatment PSA, and highest biopsy Gleason sum to predict pathologic
stage after radical prostatectomy: The Center for Prostate Disease
Research nomograms.
Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring
J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW:
Urology, 61:589-95,2003.
PDF |
6.
Predictors of extracapsular extension and positive margins
in African-American and Caucasian men.
Paquette EL, Connelly RR, Sun L, Paquette LR, Moul JW:
Urologic Oncology, 21:33-8, 2003.
Abstract
|
PDF |
7.
Pretreatment total testosterone level predicts pathologic
stage in radical prostatectomy patients with localized prostate
cancer.
Massengill JC, Sun, Moul JW, Wu H, McLeod DG, Amling C, Lance
R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue
T:
J Urol, 169:1670-5, 2003.
Abstract
|
8.
Effect of age on biochemical disease-free outcome in patients
with T1-T3 prostate cancer treated with definitive radiotherapy
in an equal-access health care system: a radiation oncology report
of the Department of Defense Center for Prostate Disease Research.
Johnstone PA, Riffenburgh RH, Moul JW, Sun L, Wu H, McLeod DG,
Kane CJ, Martin DD, Kusuda L, Lance R, Douglas R, Donahue T, Beat
MG, Foley J, Chung A, Soderdahl D, Do J, Amling CL:
Int J Radiat Oncol Biol Phys. 55:964-9, 2003.
Abstract
|
PDF< |
9.
Diagnostic potential of prostate-specific antigen expressing
epithelial cells in blood of prostate cancer patients.
Gao CL, Rawal SK, Sun L, Ali A, Connelly RR, Banez LL, Sesterhenn
IA, McLeod DG, Moul JW, Srivastava S.
Clin Cancer Res. 9(7):2545-50, 2003.
Abstract
|
PDF
|
10.
Early prostate cancer: prevention, treatment modalities,
and quality of life issues.
Moul JW, Anderson J, Penson DF, Klotz LH, Soloway MS, Schulman
CC.
Eur Urol. 44:283-93,2003.
Abstract
|
PDF
|
11.
PSA progression following radical prostatectomy and radiation
therapy: new standards in the new Millennium.
Djavan B, Moul JW, Zlotta A, Remzi M, Ravery V.
Eur Urol. 43:12-27, 2003.
Abstract
|
PDF
|
12.
Cancer-specific mortality after surgery or radiation
for patients with clinically localized prostate cancer managed
during the prostate-specific antigen era.
D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen
MH.
J Clin Oncol. 21:2163-72, 2003.
Abstract
|
PDF
|
13.
A novel neoplastic primary tumor-derived human prostate
epithelial cell line.
Ko D, Gu Y, Yasunaga Y, Nakamura K, Srivastava S, Moul JW, Sesterhenn
IA, McLeod DG, Arnstein P, Taylor DO, Hukku B, Rhim JS.
Int J Oncol. 22:1311-7, 2003.
Abstract
|
PDF |
14. Methylation of TFPI-2 gene is not the sole cause of
its silencing.
Rao CN, Segawa T, Navari JR, Xu L, Srivastava S, Moul JW, Phillips
B.
Int J Oncol. 22:843-8, 2003.
Abstract
|
PDF |
15. Limitations of tissue microarrays in the evaluation
of focal alterations of bcl-2 and p53 in whole mount derived prostate
tissues.
Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun
L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A,
Moul JW, Sesterhenn IA.
Oncol Rep. 10:223-8, 2003.
Abstract
|
PDF |
16.
Duffy antigen facilitates movement of chemokine across
the endothelium in vitro and promotes neutrophil transmigration
in vitro and in vivo.
Lee JS, Frevert CW, Wurfel MM, Peiper SC, Wong VA, Ballman KK,
Ruzinski JT, Rhim JS, Martin TR, Goodman RB.
Immunol. 170:5244-51, 2003.
Abstract
|
PDF |
17.
Generation of immortal human prostate cell lines for the study
of prostate cancer.
Rhim JS.
Methods Mol Med. 81:69-77, 2003.
Abstract
|
18.
Limited value of bone scintigraphy and computed tomography
in assessing biochemical failure after radical prostatectomy.
Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB,
Foley JP, Riffenburgh RH, Moul JW.
Urology. 61:607-11, 2003.
Abstract
|
PDF |
19.
Use of early PSA velocity to predict eventual abnormal
PSA values in men at risk for prostate cancer Prostate Cancer.
Riffenburgh RH, Amling CL.
Prostatic Dis. 6:39-44, 2003.
Abstract
|
PDF |
20.
Time trends in biochemical recurrence after radical prostatectomy:
results of the SEARCH Database.
Freedland SJ, Presti JC Jr, Amling CL, Kane CJ, Aronson WJ, Dorey
F, Terris MK;
SEARCH Database Study Group.
Urology. 61:736-41, 2003.
Abstract
|
PDF
|
 Back
to Top |  Next
Page |
|
